Michael LeBlanc
Overview
Explore the profile of Michael LeBlanc including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
4628
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sansom B, Adams B, Canales D, Doucette D, Gagnon J, LeBlanc M, et al.
Can J Hosp Pharm
. 2025 Feb;
78(1):e3596.
PMID: 39944758
No abstract available.
2.
Moseley A, LeBlanc M, Freidlin B, Shallis R, Zeidan A, Sallman D, et al.
Clin Trials
. 2025 Jan;
:17407745241304065.
PMID: 39815460
Background/aims: Randomized clinical trials often use stratification to ensure balance between arms. Analysis of primary endpoints of these trials typically uses a "stratified analysis," in which analyses are performed separately...
3.
Herrera A, LeBlanc M, Friedberg J
N Engl J Med
. 2025 Jan;
392(1):102.
PMID: 39752312
No abstract available.
4.
Unger J, Till C, Tangen C, Hershman D, Goodman P, LeBlanc M, et al.
JAMA Oncol
. 2024 Nov;
PMID: 39509091
Importance: Due to the often indolent nature of prostate cancer (PCA), treatment decisions must weigh the risks and benefits of cancer control with those of treatment-associated morbidities. Objective: To characterize...
5.
Samorodnitsky S, Othus M, LeBlanc M, Wu M
Clin Cancer Res
. 2024 Oct;
30(24):5535-5539.
PMID: 39422601
Evaluating a novel treatment in a randomized controlled trial requires comparison against existing therapies. If several existing therapies of similar benefit exist, the identification of a single control regimen may...
6.
Herrera A, LeBlanc M, Castellino S, Li H, Rutherford S, Evens A, et al.
N Engl J Med
. 2024 Oct;
391(15):1379-1389.
PMID: 39413375
Background: Incorporating brentuximab vedotin into the treatment of advanced-stage classic Hodgkin's lymphoma improves outcomes in adult and pediatric patients. However, brentuximab vedotin increases the toxic effects of treatment in adults,...
7.
Unger J, Xiao H, Vaidya R, LeBlanc M
J Clin Oncol
. 2024 Sep;
42(33):3917-3925.
PMID: 39331494
Purpose: The conduct of cancer clinical research in the United States is supported by both private and public sponsors. Industry aims to obtain new drug approvals. Federally-sponsored trials examine a...
8.
Underhill H, LeBlanc M, Macfarlane R, Hutton L
Am J Health Syst Pharm
. 2024 Jul;
81(24):1297-1304.
PMID: 38995097
Purpose: To describe the application of the Plan-Do-Study-Act quality improvement framework in the development, implementation, and evaluation of a novel pharmacy practice model in ambulatory oncology. Summary: Four iterations of...
9.
Lara Jr P, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, et al.
Prostate Cancer Prostatic Dis
. 2024 Feb;
27(3):566-570.
PMID: 38424319
Background: Circulating biomarkers of bone metabolism are significantly associated with overall survival (OS) in men with advanced prostate cancer. In the SWOG S1216 phase III trial, we showed that elevated...
10.
Janczewski L, Browner A, Cotler J, Nelson H, Ballman K, LeBlanc M, et al.
Cancer
. 2023 Dec;
130(9):1702-1710.
PMID: 38140735
Introduction: The American Joint Committee on Cancer (AJCC) staging system undergoes periodic revisions to maintain contemporary survival outcomes related to stage. Recently, the AJCC has developed a novel, systematic approach...